FOR IMMEDIATE RELEASE

“Plymouth Pharmaceuticals® launches new drug, Eczemol®, for Pediatricians, Dermatologists, and Family Practitioners”
“Eczemol®, a novel, oral medication for treating eczema/atopic dermatitis”

TULSA, Okla, December 18, 2006 -- Plymouth Pharmaceuticals®, Inc. announced today that it has launched Eczemol®, indicated for the treatment of mild to severe eczema/atopic dermatitis.

Eczema/atopic dermatitis, primarily a childhood disease, affects more than 15 million people in the US alone, making this a substantial drug market. Its primary onset is during childhood years and is marked by scaling, cracking, irritated red plaques on the skin. Usually the skin disease will go away by the time a child reaches adulthood. Although many people believe eczema is contagious, it is not, and the cause is unknown; although, it is thought to be influenced by hereditary and environmental factors and may be the result of an immune deficiency. U.S. Health Insurance companies spend over $1 billion every year to treat patients with eczema/atopic dermatitis.

Dermatologist, Dr. Steven A. Smith, MD, FACP, based in Tulsa, Okla. was searching for a better way to treat Pediatric patients with eczema and formulated Eczemol® as a result. “Eczemol® is a biochemical compound that is safe in treating children as young as one year of age, and it is completely steroid free”, Dr. Smith said, a fellow of the American College of Physicians.

“Eczemol® is a steroid-free, prescription medication for the treatment of mild to severe eczema/atopic dermatitis; the tablets can be swallowed, chewed, or dissolved by mouth for easy usage by children. Side effects are few and Eczemol’s price is competitive with other prescription treatments. Our goal is to assist Pediatricians, Dermatologists, and Family Practitioners in the fight against atopic dermatitis”, Miles Smith, the company’s Vice President, said. McKesson and Cardinal Health, two of the largest drug wholesale distributors have decided to stock Eczemol®; pharmacies routinely use one of these distributors to fill a prescription.

A retrospective clinical case study in treating eczema/atopic dermatitis with Eczemol® either in combination therapy or alone has been completed with positive results; 8 out of 10 patients stated that their eczema had improved at least moderately (data on file). Eczemol® is an effective, inexpensive, safe, and easy to use oral alternative to other prescription eczema treatments currently on the market.

For more information about Plymouth Pharmaceuticals’® products, visit www.Eczemol.com.